# A Study to Evaluate the MNV-201 in Patients With Low Risk MDS

> **NCT06465160** · PHASE1 · RECRUITING · sponsor: **Minovia Therapeutics Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)

## Key facts

- **NCT ID:** NCT06465160
- **Lead sponsor:** Minovia Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-27
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465160, "A Study to Evaluate the MNV-201 in Patients With Low Risk MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06465160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*